Could Your Expression Host Be The Problem? Q&A

Selecting an expression host is a pivotal early decision in biologics development that dictates scale-up efficiency, manufacturing costs, and long-term commercial flexibility. While CHO cells serve as the industry benchmark for complex therapeutic glycoproteins, defaulting to mammalian systems for proteins lacking complex glycosylation adds unnecessary cost and timeline delays. Fast, cost-effective microbial systems like E. coli remain ideal for cytokines and antibody fragments, while P. pastoris offers high yields alongside protein secretion to simplify downstream purification. Furthermore, host selection directly impacts protein folding, biological activity, and licensing constraints. Evaluating these scientific and financial trade-offs early across diverse expression platforms prevents costly mid-development platform switches and ensures long-term freedom to operate.

Explore these key insights to choose the ideal host for your molecule's unique pathway.